AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30758702 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 635
Study 30758702 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 635
Study 28257071 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIP (Attempted Suicide Short Intervention Program)
Number of subjects: 0
Study 28257071 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25514823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG 1320-nm laser mini-peel
Number of subjects: 36
Study 25514823 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG 2940-nm laser mini-peel
Number of subjects: 36
Study 25514823 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF)
Number of subjects: 36
Study 25514823 — intervention group
Group type: EXPERIMENTAL
Intervention: ELOS
Number of subjects: 36
Study 25514823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL)
Number of subjects: 36
Study 25514823 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesotherapy injection
Number of subjects: 36
Study 25514823 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 subjects)
Number of subjects: 36
Study 23343596 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (AMPH) 5 mg
Number of subjects: 286
Study 23343596 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (AMPH) 10 mg
Number of subjects: 286
Study 23343596 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (AMPH) 20 mg
Number of subjects: 286
Study 23343596 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine (AMPH) 0 mg (placebo)
Number of subjects: 286
Study 21112044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (5mg)
Number of subjects: 65
Study 21112044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 21112044 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50mg 3×/day over two days)
Number of subjects: 65
Study 19672133 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence therapy (during the 12 months after enrollment)
Number of subjects: 409
Study 19672133 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Adherence Rating Scale (MARS)
Number of subjects: 409
Study 19672133 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance Rating Scale (CRS)
Number of subjects: 409
Study 19672133 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopathology
Number of subjects: 409
Study 19672133 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployment and poor subjective tolerability of antipsychotics
Number of subjects: 409
Study 17088333 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Dysport) injection (500 Speywood units)
Number of subjects: 20
Study 17088333 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 20
Study 15213032 — intervention group
Group type: EXPERIMENTAL
Intervention: High food reinforcement with no SLC6A3*9 allele
Number of subjects: 88
Study 15213032 — intervention group
Group type: EXPERIMENTAL
Intervention: High food reinforcement with at least one DRD(2)*A1 allele
Number of subjects: 88
Study 15213032 — intervention group
Group type: EXPERIMENTAL
Intervention: High food reinforcement
Number of subjects: 88
Study 11591194 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated low-dose allergen exposure (1/5 of the provocative dose)
Number of subjects: 12
Study 9498445 — intervention group
Group type: EXPERIMENTAL
Intervention: Active product (milk-derived immunoglobulin)
Number of subjects: 25
Study 9498445 — intervention group
Group type: COMPARATOR
Intervention: Lactose-free placebo
Number of subjects: 25
Study 7913549 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms twice daily for 4 weeks
Number of subjects: 12
Study 7913549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2655907 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 100 mg three times daily for eight weeks
Number of subjects: 147
Study 2655907 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 100 mg three times daily for eight weeks (Group B)
Number of subjects: 147
Study 2655907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 30845794 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercise intervention (13.1±3.7 minutes per day for the first two months, 11.1±3.9 minutes per day for the next two months)
Number of subjects: 37
Study 30845794 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 37
Study 28317684 — intervention group
Group type: EXPERIMENTAL
Intervention: OVD 1 (Twinvisc)
Number of subjects: 220
Study 28317684 — intervention group
Group type: COMPARATOR
Intervention: OVD 2 (Duovisc)
Number of subjects: 220
Study 28317684 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OVDs
Number of subjects: 220
Study 26282643 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg per day
Number of subjects: 937
Study 26282643 — intervention group
Group type: COMPARATOR
Intervention: Aspirin placebo
Number of subjects: 937
Study 26282643 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch 30 g per day
Number of subjects: 937
Study 26282643 — intervention group
Group type: COMPARATOR
Intervention: Starch placebo
Number of subjects: 937
Study 24669558 — intervention group
Group type: EXPERIMENTAL
Intervention: HoLEP
Number of subjects: 40
Study 24669558 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 40
Study 21168000 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tirofiban (HDT)
Number of subjects: 1121
Study 21168000 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or no HDT)
Number of subjects: 1121
Study 19057524 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycemic index (HGI) diet, n = 19
Number of subjects: 42
Study 19057524 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index (LGI) diet, n = 23
Number of subjects: 42
Study 18260977 — intervention group
Group type: COMPARATOR
Intervention: sotalol 80 ‐ 160 mg/day
Number of subjects: 187
Study 18260977 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol 80 ‐ 160 mg/day + perindopril 4 ‐ 8 mg/day
Number of subjects: 187
Study 18260977 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol 80 ‐ 160 mg/day + rosuvastatin 5 ‐ 20 mg/day
Number of subjects: 187
Study 18260977 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol 80 ‐ 160 mg/day + omega‐3 polyunsaturated fatty acids 1 g/day
Number of subjects: 187
Study 14712346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringers lactate (RL)
Number of subjects: 66
Study 14712346 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline solution (NS)
Number of subjects: 66
Study 14712346 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 66
Study 12394551 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbscan Topography System (version 3.0)
Number of subjects: 92
Study 12394551 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic pachymeter (Ophthasonic A-Scan/Pachometer III)
Number of subjects: 92
Study 12394551 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both methods
Number of subjects: 92
Study 9748099 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich meal
Number of subjects: 42
Study 9748099 — intervention group
Group type: COMPARATOR
Intervention: Protein-poor meal
Number of subjects: 42
Study 9748099 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucide content between 125 and 150 g
Number of subjects: 42
Study 9748099 — intervention group
Group type: COMPARATOR
Intervention: Glucide content more than 150 g
Number of subjects: 42
Study 8135385 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 202
Study 8135385 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 202
Study 2718822 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid meal
Number of subjects: 12
Study 2718822 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid meal
Number of subjects: 12
Study 2718822 — intervention group
Group type: COMPARATOR
Intervention: No meal
Number of subjects: 12
Study 791587 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperazine oestrone sulphate ('Harmogen')
Number of subjects: 18
Study 791587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30358219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab combined with radical radiotherapy
Number of subjects: 62
Study 30358219 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy
Number of subjects: 62
Study 26315980 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotic treatment
Number of subjects: 81
Study 26315980 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatal connectivity index
Number of subjects: 81
Study 25204190 — intervention group
Group type: EXPERIMENTAL
Intervention: Qishen Yiqi dropping pills (0.5 g each time, three times a day for seven days)
Number of subjects: 120
Study 25204190 — intervention group
Group type: COMPARATOR
Intervention: Routine heart and diuretic treatments and placebo of Qishen Yiqi dropping pills (0.5 g each time, three times a day for seven days)
Number of subjects: 120
Study 22709547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous-LPS 0.6 ng/kg
Number of subjects: 10
Study 22709547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19357943 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages from health care providers, group-level intervention, and peer-led support groups
Number of subjects: 184
Study 19357943 — intervention group
Group type: COMPARATOR
Intervention: Brief messages from health care providers
Number of subjects: 184
Study 17921791 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nimesulide gel 1% applied 3 times a day for 30 days
Number of subjects: 74
Study 17921791 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel applied 3 times a day for 30 days
Number of subjects: 74
Study 17921791 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nimesulide gel 1%
Number of subjects: 74
Study 17921791 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 74
Study 15656699 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 800 mg as a single dose (regimen A)
Number of subjects: 18
Study 15656699 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg every 12 hours (regimen B)
Number of subjects: 18
Study 15656699 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 200 mg every 6 hours (regimen C)
Number of subjects: 18
Study 11854875 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 2 mg/kg/h for 4 hours or until rewarmed
Number of subjects: 24
Study 11854875 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 10596305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole plus isometric handgrip exercise
Number of subjects: 240
Study 10596305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole plus treadmill, symptom-limited exercise
Number of subjects: 240
Study 10596305 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole alone
Number of subjects: 240
Study 7717820 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term exercise training for 3 months (group A)
Number of subjects: 100
Study 7717820 — intervention group
Group type: COMPARATOR
Intervention: No exercise training (group B)
Number of subjects: 100
Study 2201252 — intervention group
Group type: EXPERIMENTAL
Intervention: imipenem
Number of subjects: 89
Study 2201252 — intervention group
Group type: COMPARATOR
Intervention: ceftazidime
Number of subjects: 89
Study 2201252 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftazidime + cloxacillin/amikacin
Number of subjects: 89
Study 2201252 — intervention group
Group type: EXPERIMENTAL
Intervention: imipenem + cloxacillin/amikacin
Number of subjects: 89
Study 6939000 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 0.25 mg/kg
Number of subjects: 0
Study 6939000 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 0.50 mg/kg
Number of subjects: 0
Study 6939000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31606460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled human immune globulin-eye drops (IVIG 4 mg/mL) twice a day for 8 weeks
Number of subjects: 0
Study 31606460 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 0
Study 31527581 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics analysis
Number of subjects: 0
Study 31527581 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardization of radiomics process
Number of subjects: 0
Study 28648412 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive hydration with norepinephrine administration (1ml/kg/h initially, then 3ml/kg/h crystalloid infusion after cystectomy)
Number of subjects: 166
Study 28648412 — intervention group
Group type: COMPARATOR
Intervention: Liberal hydration (6ml/kg/h standard crystalloid infusion throughout surgery)
Number of subjects: 166
Study 25564276 — intervention group
Group type: EXPERIMENTAL
Intervention: NexGard®
Number of subjects: 24
Study 25564276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bravecto™
Number of subjects: 24
Study 25564276 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 24
Study 25564276 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between NexGard® and Bravecto™
Number of subjects: 24
Study 24345529 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3% once daily
Number of subjects: 2016
Study 24345529 — intervention group
Group type: COMPARATOR
Intervention: Nepafenac 0.1% three times daily
Number of subjects: 2016
Study 21844132 — intervention group
Group type: COMPARATOR
Intervention: Imatinib alone
Number of subjects: 50
Study 21844132 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib with turmeric powder
Number of subjects: 50
Study 19605507 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg
Number of subjects: 204
Study 19605507 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg
Number of subjects: 204
Study 19605507 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.75 mg
Number of subjects: 204
Study 19605507 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg for patients receiving paclitaxel, 8 mg for those not receiving paclitaxel)
Number of subjects: 204
Study 17589339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 15 mg/kg
Number of subjects: 26
Study 17589339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17589339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 26
Study 17589339 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 26
Study 14671731 — intervention group
Group type: EXPERIMENTAL
Intervention: BDD patients
Number of subjects: 149
Study 11516600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dartmouth COOP Clinical Improvement System (DCCIS) and telephone-based nurse-educator intervention
Number of subjects: 703
Study 11516600 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 703
Study 9504319 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric restriction surgery
Number of subjects: 487
Study 9504319 — intervention group
Group type: COMPARATOR
Intervention: Conventional weight reduction treatment
Number of subjects: 487
Study 11271224 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA therapy (8‐methoxypsoralen and UVA irradiation)
Number of subjects: 75
Study 3069135 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion at 1 microgram/min for up to 20 min
Number of subjects: 131
Study 3069135 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 131
Study 3069135 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 131
Study 3069135 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion (mean dosage of 18.5 ng/min/kg)
Number of subjects: 131
Study 3069135 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic attacks during isoproterenol infusions
Number of subjects: 131
Study 30305114 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid intervention
Number of subjects: 10000
Study 30305114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 10000
Study 27824264 — intervention group
Group type: EXPERIMENTAL
Intervention: Luphere 3M Depot (leuprolide acetate dose of 11.25 mg)
Number of subjects: 20
Study 27824264 — intervention group
Group type: COMPARATOR
Intervention: Lucrin Depot (leuprolide acetate dose of 11.25 mg)
Number of subjects: 20
Study 26609031 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 25 mg dexketoprofen trometamol
Number of subjects: 144
Study 26609031 — intervention group
Group type: EXPERIMENTAL
Intervention: Two puff lidocaine sprays on cervical mucosa
Number of subjects: 144
Study 26609031 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg pethidine
Number of subjects: 144
Study 26609031 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg intravenous paracetamol
Number of subjects: 144
Study 26609031 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 144
Study 26609031 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 144
Study 24345424 — intervention group
Group type: EXPERIMENTAL
Intervention: Video decision aid with patient narratives
Number of subjects: 56
Study 24345424 — intervention group
Group type: EXPERIMENTAL
Intervention: Text decision aid with patient narratives
Number of subjects: 56
Study 24345424 — intervention group
Group type: COMPARATOR
Intervention: Video decision aid without patient narratives (control)
Number of subjects: 56
Study 24345424 — intervention group
Group type: COMPARATOR
Intervention: Text decision aid without patient narratives (control)
Number of subjects: 56
Study 16389004 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached pushing
Number of subjects: 320
Study 16389004 — intervention group
Group type: COMPARATOR
Intervention: Uncoached pushing
Number of subjects: 320
Study 12594673 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution MRI
Number of subjects: 98
Study 10703393 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus plus 'low-dose' MMF (TMBIR)
Number of subjects: 53
Study 10703393 — intervention group
Group type: COMPARATOR
Intervention: Neoral plus 'low-dose' MMF (NMBIR)
Number of subjects: 53
Study 8603630 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 73
Study 8603630 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB)
Number of subjects: 73
Study 8603630 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 73
Study 1746006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (400 mg/day)
Number of subjects: 0
Study 1746006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (1 to 30 microM) with subthreshold concentration of NO
Number of subjects: 0
Study 1746006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole with subthreshold concentration of PGI2
Number of subjects: 0
Study 1746006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole with subthreshold concentration of NO and PGI2
Number of subjects: 0
Study 1746006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7037035 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide, 200 micrograms twice daily
Number of subjects: 30
Study 7037035 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate, 100 micrograms four times daily
Number of subjects: 30
Study 7037035 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide and Beclomethasone dipropionate
Number of subjects: 30
Study 31684921 — intervention group
Group type: EXPERIMENTAL
Intervention: In-clinic physical therapy intervention including manual therapy, stretching, strengthening, and neuromuscular functional training.
Number of subjects: 0
Study 31684921 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program (HEP) designed for patients to perform without PT supervision.
Number of subjects: 0
Study 28471713 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter Advance Directive (LAD)
Number of subjects: 400
Study 26059526 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin tablets for 6 months
Number of subjects: 744
Study 22763199 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Care (EC): brochure, brief negotiated interview, 6 weeks of nicotine patches, and a telephone call
Number of subjects: 88
Study 22763199 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC): smoking cessation brochure
Number of subjects: 88
Study 21720782 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Action intervention
Number of subjects: 0
Study 21720782 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19818720 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified duck embryo vaccine (PDEV, Vaxirab)
Number of subjects: 152
Study 19818720 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified chick embryo cell vaccine (PCEC, Rabipur)
Number of subjects: 152
Study 19818720 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified vero cell rabies vaccine (PVRV, Verorab)
Number of subjects: 152
Study 16677223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 702
Study 16677223 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief therapy (BT)
Number of subjects: 702
Study 16677223 — intervention group
Group type: COMPARATOR
Intervention: Matched care approach (CAU)
Number of subjects: 702
Study 15549275 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole drink (containing 37.5 g glucose, 75 mg caffeine, ginseng and ginkgo biloba)
Number of subjects: 20
Study 15549275 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 20